Acrivon Therapeutics, Inc. Common Stock (ACRV)
Largest Insider Buys in Sector
ACRV Stock Price History Chart
ACRV Stock Performance
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Insider Activity of Acrivon Therapeutics, Inc. Common Stock
Over the last 12 months, insiders at Acrivon Therapeutics, Inc. Common Stock have bought $20M and sold $0 worth of Acrivon Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Acrivon Therapeutics, Inc. Common Stock have bought $33.68M and sold $97,579 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (10 percent owner) — $360.01M.
The last purchase of 2,353,000 shares for transaction amount of $20M was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2024‑04‑11.
List of Insider Buy and Sell Transactions, Acrivon Therapeutics, Inc. Common Stock
| 2024-04-11 | 10 percent owner | 2.35M 8.4743% | $8.50 | $20M | -18.41% | |||
| 2023-06-26 | Sale | 10 percent owner | 16 <0.0001% | $12.93 | $207 | -48.66% | ||
| 2023-06-15 | Sale | 10 percent owner | 2,056 0.0106% | $12.14 | $24,960 | -39.33% | ||
| 2023-06-14 | Sale | 10 percent owner | 893 0.0046% | $12.13 | $10,832 | -38.40% | ||
| 2023-06-13 | Sale | 10 percent owner | 3,000 0.0156% | $12.30 | $36,900 | -40.28% | ||
| 2023-06-12 | Sale | 10 percent owner | 2,000 0.0105% | $12.34 | $24,680 | -40.91% | ||
| 2022-11-17 | 3.39M 17.9519% | $12.50 | $42.37M | -21.95% | ||||
| 2022-11-17 | 10 percent owner | 400,000 2.1185% | $12.50 | $5M | -21.95% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 5360858 17.2174% | $5.58 | 1 | 0 | |
| RA CAPITAL MANAGEMENT, L.P. | 4384206 14.0807% | $5.58 | 1 | 0 | <0.0001% | |
| Chione Ltd | 10 percent owner | 3848632 12.3606% | $5.58 | 1 | 5 | <0.0001% |